Victory Capital Management
ALDX icon

Victory Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Victory Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-39,930
Closed -$267K – 2539
2023
Q3 		$267K Sell
39,930
-142,520
-78% -$1.06M ﹤0.01% 2144
2023
Q2 		$1.53M Buy
182,450
+44,170
+32% +$435K ﹤0.01% 1484
2023
Q1 		$1.37M Sell
138,280
-36,010
-21% -$255K ﹤0.01% 1534
2022
Q4 		$1.21M Buy
174,290
+106,900
+159% +$611K ﹤0.01% 1634
2022
Q3 		$360K Buy
+67,390
New +$404K ﹤0.01% 2183
2020
Q2 		– Sell
-7,456
Closed -$18K – 2521
2020
Q1 		$18K Buy
+7,456
New +$33.5K ﹤0.01% 3120
2019
Q4 		– Sell
-4,257
Closed -$22K – 2646
2019
Q3 		$22K Buy
+4,257
New +$22.9K ﹤0.01% 3008

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management's ALDX Position: Q4 2023 in Review

Victory Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 39,930 shares — an estimated $267K sold.

Victory Capital Management first reported a position in ALDX in Q3 2019 and held it in 7 quarters. The position peaked at $1.53M in Q2 2023. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

  • Victory Capital Management reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Victory Capital Management sold 39,930 Aldeyra Therapeutics shares in Q4 2023, an estimated $267K.
  • Victory Capital Management first reported a position in Aldeyra Therapeutics in Q3 2019 and held it in 7 quarters.
  • Victory Capital Management's Aldeyra Therapeutics position peaked at $1.53M in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on Victory Capital Management's 13F filing for Q4 2023, filed 5 Feb 2024.